ArticleBMC cancer2019
Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Physical activity, sedentary behavior and ovarian cancer risk in Asian populations: a scoping review and meta-analysis.BMC cancer · 2026Pooled it
- Risk of gynaecologic cancers in women with metabolic syndrome: A systematic review & meta-analysis.The Indian journal of medical research · 2025Pooled it
- Anthropometric factors and the risk of ovarian cancer: A systematic review and meta-analysis.Cancer reports (Hoboken, N.J.) · 2022Pooled it
- Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Gynecologic oncology · 2024Trial
- Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.Nature communications · 2024Trial
- Clinicopathological characteristics and potential impact of previous treatment history in metachronous contralateral breast cancer: Insights from a real-world retrospective study.Oncology letters · 2026Article
- Article
- Re-Thinking Pharmacokinetics in Ovarian Cancer: What Do Organoids Add?International journal of molecular sciences · 2026Review
- XGBoost-Cox modeling with SHAP analysis for survival prediction in ovarian cancer patients: a retrospective cohort study.BMC cancer · 2026Article
- Outcomes and Long-term Follow-up of Epithelial Ovarian Cancer: Experience from the Lead Cancer Center of Pakistan.Journal of cancer & allied specialties · 2026Article
- Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older.JAMA network open · 2026Article
- Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization.BMC cancer · 2026Article
- Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021.International journal of surgery (London, England) · 2026Article
- Evaluation of drug options for epithelial ovarian cancer (EOC) treatment using the analytical hierarchy process improves decision-making transparency.Discover oncology · 2025Article
- Hepatoma-derived growth factor and non-coding RNA network in ovarian cancer patients.Biochemistry and biophysics reports · 2025Article
- Analysis of global ovarian cancer disease burden and its changing trend from 1990 to 2021.BMC women's health · 2025Article
- Trends in the Incidence of Ovarian Cancer Among Premenopausal and Postmenopausal Women in the United States, 2001 to 2021.Cancers · 2025Article
- Increased risk of young-onset ovarian cancer in women with non-alcoholic fatty liver disease: A nationwide cohort study of 2.3 million women aged 20-39 years.Scientific reports · 2025Article
- Research Progress of Electrochemical Biosensors for Diseases Detection in China: A Review.Biosensors · 2025Review
- Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOvarian cancer (OC) is the seventh most common malignancy worldwide and the most lethal gynaecological malignancy. We aimed to explore global geographical patterns and temporal trends from 1973 to 2015 for 41 countries in OC incidence and especially to analyse the birth cohort effect to gain further insight into the underlying causal factors of OC and identify countries with increasing risk of OC.
methodsOC data were drawn from the Cancer Incidence in Five Continents databases and online databases published by governments. The joinpoint regression model was applied to detect changes in OC trends. The age-period-cohort model was applied to explore age and birth cohort effects.
resultsThe age-standardized rate of OC incidence ranged from 3.0 to 11.4 per 100,000 women worldwide in 2012. The highest age-standardized rate was observed in Central and Eastern Europe, with 11.4 per 100,000 women in 2012. For the most recent 10-year period, the increasing trends were mainly observed in Central and South America, Asia and Central and Eastern Europe. The largest significant increase was observed in Brazil, with an average annual percentage change of 4.4%. For recent birth cohorts, cohort-specific increases in risk were pronounced in Estonia, Finland, Iceland, Lithuania, the United Kingdom, Germany, the Netherlands, Italy, Malta, Slovenia, Bulgaria, Russia, Australia, New Zealand, Brazil, Costa Rica, Ecuador, India, Japan, the Philippines and Thailand.
conclusionsDisparities in the incidence and risk of OC persist worldwide. The increased risk of birth cohort in OC incidence was observed for most countries in Asia, Central and Eastern Europe, and Central and South America. The reason for the increasing OC risk for recent birth cohorts in these countries should be investigated with further epidemiology studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.